project-focuses-clinical-46.html
Novo Annual Review 2016
47 / 71
class of 2016 amra is a healthcare it startup. the
company
is
developing
an automated image analysis platform for a full body mri scan. the platform will be able to quantify fat and muscle volumes across the body. corwave is a french medical device
company
. corwave is
developing
a unique left ventricular assist device (lvad) for congestive heart failure (chf). http://
www
.corwave.fr/ heparegenix gmbh is a german
company
that is
developing
a new treatment to promote liver regeneration. hoba therapeutics is
developing
a treatment for neuropathic pain. macrophage pharma is a new uk immune-oncology
company
that is working on improving the response rate to a range of cancers. merozyne therapeutics ab is
developing
a pharmaceutical treatment against mdc1a, a rare and severe form of muscular dystrophy. http://merozyne.com/ nmd pharma is
developing
novel treatments for neuromuscular diseases such as myasthenia gravis and als. existing portfolio acesion pharma aps develops new therapies for the medical treatment of atrial fibrillation, the most common type of cardiac arrhythmia.
www
.acesionpharma.com adenium biotech aps focuses on the development and commercialisation of novel antibiotics for the treatment of multi-drug resistant bacterial infections.
www
.adeniumbiotech.com avilex pharma aps develops dimeric peptides that target psd95 for the treatment of ischaemic stroke.
www
.avilexpharma.com biosyntia is a biotech startup within synthetic biology and metabolic engineering. the
company
develops biocatalysts at an unprecedented speed and efficiency by employing a patent pending high- throughput screening technology. http://biosyntia.com/ inthera bioscience is a swiss biotech
company
targeting hpv+ head and neck cancer (hnscc) and/ or hpv+ genitourinary cancer as initial indication(s). forendo pharma ltd develops drugs for tissue-specific regulation of sex hormone effects.
www
.forendo.com galecto biotech ab develops anti-fibrotic and anti- inflammatory treatments based on small molecules of galectin modulators. the
company
?s lead programme is in development for idiopathic pulmonary fibrosis.
www
.galecto.com io biotech aps is
developing
a novel immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. http://
www
.iobiotech.com/ lysogene sa is a clinical-stage biotech
company
working in the field of gene therapy. the
company
?s therapies target severe genetic pathologies of the central nervous system in children.
www
.lysogene.com minervax aps is
developing
a novel vaccine candidate against group b streptococci, which is the leading cause of life-threatening bacterial infections in newborn babies.
www
.minervax.com reapplix aps is
developing
a device that produces a fully autologous dressing for wound care, particularly difficult-to-heal diabetic foot ulcers.
www
.reapplix.com rspr pharma is
developing
an oral anti-asthmatic drug that provides mast cell control by inhibiting both induced and basal release of asthma mediators. http://
www
.rsprpharma.com/ novo seeds portfolio companies adenium biotech hoba therapeutics 47 novo seeds
novo-2016-portfolio-48.html
